ArticleFrontiers in cardiovascular medicine2026
Case Report: When inotropy backfires-dobutamine-associated eosinophilic myocarditis.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Eosinophilic myocarditis (EM) is a rare form of myocarditis that is often triggered by drug hypersensitivity reactions. We describe the case of a 55-year-old man who presented with cardiogenic shock that rapidly progressed despite dual inotropic therapy, ultimately requiring left ventricular assist device implantation. A left ventricular apical core biopsy demonstrated eosinophilic infiltration consistent with EM. After comprehensive evaluation of the possible etiologies, dobutamine was identified as the most likely offending agent. Following discontinuation of dobutamine and initiation of corticosteroid therapy, ventricular function and hemodynamics improved, supporting a diagnosis of dobutamine-associated EM. Clinicians should consider drug-induced EM in patients with refractory cardiogenic shock receiving dobutamine. Alternative inotropic agents such as milrinone or epinephrine should be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.